Veröffentlichungen
Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer
Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.
Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study
Filename | 426. Lumry et al., Impact of Lana QoL HAE HELP study,Allergy2021.pdf |
Filesize | 710,56 kB |
Version | o.426 |
Date added | Juni 1, 2021 |
Downloaded | 2 times |
Category | Original Work |
Tags | AE-QoL, Hereditary Angioedema, Lanadelumab, long-term prophylaxis, Quality of life |
Authors | Lumry, W. R., Weller, K., Magerl, M., Banerji, A., Longhurst, H. J., Riedl, M. A., Lewis, H. B., Lu, P., Devercelli, G., Jain, G., and Maurer, M. |
Citation | Lumry, W. R., Weller, K., Magerl, M., Banerji, A., Longhurst, H. J., Riedl, M. A., Lewis, H. B., Lu, P., Devercelli, G., Jain, G., and Maurer, M.: Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy 2021: 76; 1188-1198. |
Corresponding authors | Lumry, W. R. |
DocNum | o.426 |
DocType | |
IF | 14.71 |
Publisher | Allergy |
ReleaseDate | 2021 |
Background: An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE).
Methods: Patients with HAE-1/2 received either lanadelumab 150 mg every 4 weeks (q4wks; n = 28), 300 mg q4wks (n = 29), 300 mg every 2 weeks (q2wks; n = 27), or pla-cebo (n = 41) for 26 weeks (days 0–182). The Angioedema Quality of Life Questionnaire (AE-QoL) was administered monthly, consisting of four domain (functioning, fatigue/mood, fears/shame, nutrition) and total scores. The generic EQ-5D-5L questionnaire was administered on days 0, 98, and 182. Comparisons were made between placebo and (a) all lanadelumab-treated patients and (b) individual lanadelumab groups for changes in scores (day 0–182) and proportions achieving the minimal clinically impor-tant difference (MCID, −6) in AE-QoL total score.
Results: Compared with the placebo group, the lanadelumab total group demon-strated significantly greater improvements in AE-QoL total and domain scores (mean change, −13.0 to −29.3; p < 0.05 for all); the largest improvement was in functioning. A significantly greater proportion of the lanadelumab total group achieved the MCID (70% vs 37%; p= 0.001). The lanadelumab 300 mg q2wks group had the highest pro-portion (81%; p = 0.001) and was 7.2 times more likely to achieve the MCID than the placebo group. Mean EQ-5D-5L scores at day 0 were high in all groups, indicating low impairment, with no significant changes at day 182.
Conclusion: Patients with HAE-1/2 experienced significant and clinically meaningful improvements in HRQoL measured by AE-QoL following lanadelumab treatment in the HELP Study.
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.